Eurofins Discovery Acquires CALIXAR, Expanding Integrated Drug Discovery Capabilities and Expertise
Eurofins Discovery Acquires CALIXAR, Expanding Integrated Drug Discovery Capabilities and Expertise
Release date: 4/5/2023
SAN DIEGO, CA – April 5, 2023 – Eurofins Discovery, the leading provider of products and services for the drug discovery industry, today announced its acquisition of CALIXAR, a leader in delivering the highest-quality membrane proteins for life science.
The acquisition brings key capabilities in membrane protein production of highly druggable targets to Eurofins Discovery and Eurofins DiscoverX®, and further solidifies their scientific leadership in G Protein-Coupled Receptors (GPCRs) and ion channels. Expanding expertise in these key areas augments the company’s Integrated Drug Discovery platform, DiscoveryOne™, and its Biophysics and Biotherapeutics platforms.
The deal with the France-based CALIXAR brings its functional membrane protein target technology along with its patented surfactants, detergents and growing pipeline of purified membrane protein targets into the extensive Eurofins DiscoverX product portfolio.
The addition of CALIXAR supports Eurofins Discovery’s strategy to be the partner of choice to the pharmaceutical and biotech industry by providing its drug discovery experience, knowledge, leading assay portfolio against highly druggable targets, and proven success in supporting the development of new therapeutics. It brings expertise in developing novel approaches to isolate full-length native membrane proteins of therapeutic target classes, such as GPCRs, ion channels, transporters, viral targets, and other membrane receptors at the highest purity levels, thereby preserving their original structure and function.
CALIXAR augments Eurofins Discovery’s capabilities and innovative methods to support and accelerate drug discovery research and development, and to capitalize on the growing R&D outsourcing market.
Media Contact
Aida Yodites
aidayodites@eurofinsus.com
About Eurofins Discovery and Eurofins DiscoverX
Eurofins Discovery is recognized as an industry-leading CRO with trusted product solutions provider, Eurofins DiscoverX. We provide over 23,000 products and services to drug discovery researchers, and offer the largest portfolio of solutions addressing early discovery through pre-clinical ADME-toxicology into development. Our cross-disciplinary scientific experts support discovery programs from concept to clinic. With global R&D operations, we develop cutting-edge assays, stable cell lines, membrane preps, enzymes & reagents, and support discovery across all major drug target classes, including GPCRs, kinases and ion channels. Eurofins Discovery’s capabilities, expertise, knowledge and skill sets enable the company to provide clients the benefit of being able to work with a single outsourcing provider (CRO) for all their drug discovery programs.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins network of companies believes that it is the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing and in vitro diagnostic products.
With over 61,000 staff across a network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
About CALIXAR
Founded in 2011 by Emmanuel DEJEAN, Ph.D., and Pierre Falson, Ph.D., DR CNRS, in Lyon, France, CALIXAR is a premium membrane protein provider for drug discovery. CALIXAR’S mission is to provide membrane proteins among the best in the world for developing antibodies, formulating vaccines and/or discovering primary leads through Structure-Based Drug Design or High Throughput Screening assays. CALIXAR’S technology is capable of producing high quality, native, wild-type, unaltered, unmutated and untruncated targets for antibody development and drug discovery projects. They are unique in the market and are at the forefront of Membrane Protein technology.